<DOC>
	<DOCNO>NCT00125554</DOCNO>
	<brief_summary>The purpose study test whether metyrapone effective safe augment agent treatment major depression .</brief_summary>
	<brief_title>Metyrapone Additive Treatment Major Depression</brief_title>
	<detailed_description>The investigator ' understanding neuroendocrine pathophysiology depression make significant progress recent year , help develop new remedy . Alterations hypothalamic-pituitary-adrenocortical ( HPA ) axis consistent pathological endocrine finding depression . Hence , attempt make treat depression directly target HPA-axis activity . Currently , three major pathway investigate : - Administration CRH-antagonists ; - Administration glucocorticoid-receptor-antagonists ; - Treatment steroid-synthesis inhibitor like ketoconazole , aminogluthethimide metyrapone . The investigator ' aim conduct first prospective , randomize , placebo-controlled , double-blind clinical trial metyrapone additive treatment depression . Metyrapone prefer , since compound inhibits selectively 11β-hydroxylase 11β-hydroxysteroid dehydrogenase type 1 ( 11β-HSD-1 ) , thereby exert direct effect within central nervous system ( CNS ) . The additive approach apply intend inclusion severely depressed patient make pure placebo group ethically challenge . Furthermore , continuous use antidepressant allow standardized follow double-blind period . The hypothesis test , whether metyrapone exerts potentiate effect standard antidepressant therapy whether early onset-of-action improve overall sustained treatment response achieve . Since GR/MR distribution well 11β-HSD-1 activity subject sexual dimorphism human , sample prospectively stratify gender balance treatment two select serotonergic antidepressant , allow analysis gender effect neuroendocrine treatment effect .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Metyrapone</mesh_term>
	<criteria>Diagnosis major depressive disorder ; single recurrent accord DSMIV criterion ( 296.2 296.3 ) A minimum baseline Hamilton score 18 point Hamilton Rating Scale Depression ( HamD ; 21item version ) Age 18 75 year A drug free period least 5 day antidepressant , antipsychotic , mood stabilizer medication except mild antihypertensive agent A negative urinary drug screen diagnosis A current DSMIV diagnosis axis I psychiatric disorder Serious medical condition , especially associate adrenal insufficiency Pregnancy , nurse refusal use reliable method birth control woman . Participants randomly assign study group meet criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>Clinical trial</keyword>
	<keyword>double-blind</keyword>
	<keyword>randomize placebo-controlled trial</keyword>
	<keyword>metyrapone</keyword>
	<keyword>Major Depression</keyword>
</DOC>